TRVI Stock Analysis: Buy, Sell, or Hold?
TRVI - Trevi Therapeutics, Inc. Common Stock
$14.78
0.57 (4.01%)
▲
5d:
+9.48%
30d:
-1.99%
90d:
+32.44%
HOLD
MODERATE Confidence
Analysis Updated: Jun 12, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Smart Money Accumulation
None View Scanner →
Strength: 7.6/10
Get Alerted When TRVI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: TRVI shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: TRVI shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: TRVI is currently trading at $14.78, which is considered extended relative to its 30-day fair value range of $13.52 to $14.65.
Technical Outlook: Technically, TRVI is in a strong uptrend. The price is approaching resistance at $15.03. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.0% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $23.90 (+68.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, TRVI is in a strong uptrend. The price is approaching resistance at $15.03. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.0% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $23.90 (+68.2%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$13.52 -
$14.65
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
56.3%
Protect Your Profits
Holding TRVI? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.0%)
- BULLISH: Trading 68.2% below Wall St target ($23.90)
Trading Range Analysis
30-Day Trading Range
$13.52 -
$14.65
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$13.20
Resistance Level
$15.03
Current Trend
Strong Uptrend
Technical data as of
Jun 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-25.48
Wall Street Target
$23.90
(+68.2%)
Share & Embed Analysis
Last updated: June 15, 2026 1:22 PM ET
Data refreshes hourly during market hours. Next update: 2:22 PM
Data refreshes hourly during market hours. Next update: 2:22 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TRVI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$439 | 57 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 53 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$198 | 58 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 66 BUY |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 48 HOLD |
Advanced TRVI Option Strategies
Professional options setups generated by AI based on today's TRVI price and gamma walls.
